Prognostic Implication of ERCC1 Protein Expression in Resected Oropharynx and Oral Cavity Cancer
Overview
Authors
Affiliations
Background: Excision repair cross complement group 1 (ERCC1) expression is a predictive biomarker for platinum-containing treatment in squamous cell carcinoma of head and neck (SCCHN). However, the prognostic significance after surgical resection is not well understood.
Methods: Oropharynx (n=143) or oral cavity (n=61) SCCHN patients undergoing surgery were included. ERCC1 protein expression and HPV status were assessed by ERCC1 and p16 immunohistochemistry.
Results: The ERCC1, over-expressed in 66.7% of patients, was associated with oral cavity cancer (P<0.001), well differentiation (P=0.036), and HPV negativity (P<0.001). In TCGA database, ERCC1 mRNA upregulation was enriched in HPV-negative and oral cavity cancers, and associated with HRAS mutation (P<0.001). The prognostic role of ERCC1 was not different according to HPV status. High ERCC1 expression showed a trend toward poor prognosis in patients with an advanced stage (P=0.079) with marginal significance.
Conclusions: The ERCC1 expression was not prognostic in surgically resected oropharynx/oral cavity SCCHN, irrespective of HPV status. However, it could provide additional prognostic information for advanced stage patients.
Guo T, Zamuner F, Ting S, Chen L, Rooper L, Tamayo P Front Oncol. 2024; 14:1336577.
PMID: 38505587 PMC: 10949886. DOI: 10.3389/fonc.2024.1336577.
Lei H, He A, Jiang Y, Ruan M, Han N Front Oncol. 2022; 12:1031944.
PMID: 36338767 PMC: 9634729. DOI: 10.3389/fonc.2022.1031944.
Wang Y, Fang P, Su C, Chen Y, Huang J, Huang M Oncol Lett. 2021; 21(6):450.
PMID: 33868488 PMC: 8045162. DOI: 10.3892/ol.2021.12711.